| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.39 | 4e-28 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.33 | 6e-24 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.34 | 2e-22 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.37 | 9e-15 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | 0.27 | 3e-14 |
| mRNA | ATRA | CTRPv2 | pan-cancer | AAC | 0.25 | 4e-13 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | 0.24 | 2e-12 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.26 | 2e-12 |
| mRNA | (5Z)-7-Oxozeaenol | GDSC1000 | pan-cancer | AAC | 0.22 | 2e-12 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | 0.23 | 6e-12 |